<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524118</url>
  </required_header>
  <id_info>
    <org_study_id>1654-002</org_study_id>
    <secondary_id>MK-1654-002</secondary_id>
    <secondary_id>2017-005062-21</secondary_id>
    <nct_id>NCT03524118</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of MK-1654 in Infants (MK-1654-002)</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      incidence of anti-drug antibodies (ADAs) of single ascending doses of MK-1654 in healthy
      pre-term (born at 29 to 35 weeks gestational age) and full-term (born at &gt;35 weeks
      gestational age) infants. Key safety and tolerability variables will be reviewed after each
      panel prior to administering the next-highest dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single ascending dose</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants experiencing a solicited injection site adverse event (AE)</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection site AEs will be monitored from Day 1 to Day 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a solicited systemic AE</measure>
    <time_frame>Up to Day 5</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs will be monitored from Day 1 to Day 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a serious AE (SAE)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>An SAE is any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant injury/incapacity; is a congenital anomaly/birth defect; or is an other important medical event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum-concentration time curve from zero to infinity (AUC0-∞)</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>AUC0-∞ is a measure of the extrapolated mean concentration in serum from dosing to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of MK-1654</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>Cmax is the highest observed serum drug concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum serum concentration (Tmax) of MK-1654</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>Tmax is the amount of time required to reach Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) of MK-1654</measure>
    <time_frame>At designated time points (up to 1 year post-dose)</time_frame>
    <description>t1/2 is the time required for 50% of drug to be cleared from serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 7 (C7days)</measure>
    <time_frame>Day 7</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 14 (C14days)</measure>
    <time_frame>Day 14</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 90 (C90days)</measure>
    <time_frame>Day 90</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 150 (C150days)</measure>
    <time_frame>Day 150</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of MK-1654 on Day 365 (C365days)</measure>
    <time_frame>Day 365</time_frame>
    <description>Serum concentration of MK-1654 will be measured on Day 365.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 90</measure>
    <time_frame>Day 90</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 150</measure>
    <time_frame>Day 150</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 150.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of ADAs to MK-1654 on Day 365</measure>
    <time_frame>Day 365</time_frame>
    <description>Titers of ADAs to MK-1654 will be measured on Day 365.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Respiratory Tract Infection</condition>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Panel A: Pre-term MK-1654 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 1 via intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: Pre-term MK-1654 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 2 via IM injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C: Pre-term MK-1654 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 3 via IM injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D: Pre-term MK-1654 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term infants will receive MK-1654 Dose 4 via IM injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E: Full-term MK-1654 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Full-term infants will receive MK-1654 Dose 4 via IM injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pre-term infants will receive placebo via IM injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1654</intervention_name>
    <description>Single ascending doses of MK-1654 will be administered via IM injection.</description>
    <arm_group_label>Panel A: Pre-term MK-1654 Dose 1</arm_group_label>
    <arm_group_label>Panel B: Pre-term MK-1654 Dose 2</arm_group_label>
    <arm_group_label>Panel C: Pre-term MK-1654 Dose 3</arm_group_label>
    <arm_group_label>Panel D: Pre-term MK-1654 Dose 4</arm_group_label>
    <arm_group_label>Panel E: Full-term MK-1654 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (0.9% sodium chloride [NaCl]) will be administered via IM injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  is healthy, based on screening safety laboratory, medical history, and physical
             examination results

          -  is a pre-term infant (born at 29 weeks to 35 weeks gestational age [inclusive]) or a
             full-term infant (born at over 35 weeks gestational age), as confirmed in medical
             records

          -  weighs ≥2 kg at screening

        Exclusion Criteria:

          -  has been recommended to receive palivizumab per local standard of care

          -  has ≥1 documented out-of-range safety laboratory results (adjusted for age) at the
             time of screening

          -  has a known hypersensitivity to any component of the respiratory syncytial virus (RSV)
             monoclonal antibody

          -  has a history of congenital or acquired immunodeficiency (e.g., splenomegaly)

          -  has documented human immunodeficiency virus (HIV) infection, hepatitis B (HBsAg
             positive), or hepatitis C (HCV ribonucleic acid [RNA] positive)

          -  has known history of functional or anatomic asplenia

          -  has a diagnosis of failure to thrive within 14 days of screening

          -  has known or history of a coagulation disorder contraindicating intramuscular
             injection

          -  has received or is expected to receive blood products (except irradiated platelets)
             within 3 months prior to enrollment

          -  has prior known documented RSV infection

          -  has hemodynamically significant congenital heart disease

          -  has chronic lung disease of prematurity requiring ongoing medical therapy

          -  has a history or current evidence of any condition, therapy, lab abnormality or other
             circumstance that, in the opinion of the investigator, might expose the participant to
             undue risk by participating in the study, confound the results of the study, or
             interfere with the participant's participation for the full duration of the study

          -  has any history of malignancy prior to randomization

          -  if any of the following apply, the Day 1 visit may be rescheduled for a time when
             these criteria are not met:

          -  has had a recent febrile illness (rectal temperature 38.1°C [100.5°F] or higher or
             axillary temperature 37.8°C [100.0°F] or higher) within 72 hours pre-dose

          -  is not up-to-date on required vaccinations per local pediatric vaccine schedule at
             time of screening

          -  has received inactivated or component vaccines (eg, influenza, hepatitis B) less than
             14 days pre-dose

          -  has received live, attenuated, non-study licensed pediatric vaccines (e.g., Bacillus
             Calmette-Guerin vaccine) less than 30 days pre-dose

          -  has received any prior vaccine or monoclonal antibody (mAb) for the prevention of RSV

          -  is currently participating in or has participated in an interventional clinical study
             with an investigational compound or device at any time prior to first dose
             administration or while participating in this current study (participants enrolled in
             observational studies may be included and will be reviewed on a case-by-case basis for
             approval by the Sponsor)

          -  has enrolled previously in this study and been discontinued

          -  participant's mother participated in a RSV vaccine clinical study while pregnant and
             participant is ≤3 months of chronological age

          -  is unable to provide blood sample at screening

          -  cannot be adequately followed for safety according to the protocol plan

          -  has a parent/legally acceptable representative who is unlikely to adhere to study
             procedures, keep appointments, or is planning to relocate during the study

          -  is, or has, an immediate family member (eg, spouse, parent/guardian, sibling, or
             child) who is directly involved with the study at the site or with the Sponsor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital - Colorado ( Site 0067)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-777-4163</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Next Phase Research Alliance, LLC ( Site 0075)</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-615-9697</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates ( Site 0025)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>786-212-4187</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children ( Site 0027)</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>808-369-1247</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0081)</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>785-270-4327</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital ( Site 0037)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center ( Site 0032)</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>603-653-6070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital ( Site 0029)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>WakeMed Health and Hospitals ( Site 0033)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-350-5585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0031)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-636-4463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association ( Site 0066)</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>937-424-9294</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research ( Site 0028)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0039)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>409-772-1696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc. ( Site 0026)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Multicare Institute For Research And Innovation ( Site 0035)</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-403-0366</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin American Family Children's Hospital ( Site 0068)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-263-8558</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica Bradford Hill ( Site 0103)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7650698</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Florida ( Site 0050)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8242238</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56993453388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidad de Chile ( Site 0104)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56995322132</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Padre Hurtado ( Site 0102)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8880465</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994346039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital San Vicente de Paul ( Site 0097)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5744441333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0098)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>111221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573108239876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedPlus Medicina Prepagada S.A. ( Site 0095)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5715226772</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Universitaria de Ciencias de la Salud - Sociedad de Cirugia ( Site 0099)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111411</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573115892472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0090)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5723319090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 0071)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220721696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0073)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222280270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0072)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234100987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital ( Site 0262)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119834283</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tygerberg Hospital ( Site 0261)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27726111221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago ( Site 0241)</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna [La Coruna]</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0242)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Korea, Republic of</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 11, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

